Back to search results

Study Using Hyperpolarized 13C-Pyruvate for Pancreatic Cysts

This study is looking at whether a special imaging technique using Hyperpolarized 13C-Pyruvate (a drug given by injection) can help doctors tell the difference between low-risk (benign) and high-risk (malignant) pancreatic cysts. You could join if you are 18 or older, have pancreatic cysts, and are scheduled to have surgery to remove them. The main goal is to see if there are any side effects from the Hyperpolarized 13C-Pyruvate. The study aims to enroll 20 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with an enrollment goal of 20 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo Hyperpolarized 13C-Pyruvate imaging before your pancreatic cyst surgery. A small tissue sample from your surgery would also be used for further testing.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for side effects through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05873699

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Suspended
PHASE1Ages 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~20 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:Hyperpolarized 13-C-pyruvate

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over Through study completion; an average of 1 year.

Conditions

Pancreatic Cyst

Explore related trials

Pancreatic Cyst

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Florencia McAllister, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Patients with pancreatic cyst/s
Patients who will undergo surgical resection (or cyst wall biopsy) of pancreatic cysts
Patients able to understand and willing to sign a written informed consent document
Both English-speaking and non-English-speaking patients are eligible for participation

Exclusion

Contraindication to MRI
Electrically, magnetically, or mechanically activated implants that would preclude MRI
Allergy to Gadavist IV contrast
History of cardiac arrhythmias
Pregnancy or breastfeeding women
Women of child-bearing age that are sexually active and not using birth control
Cognitively impaired individuals
Weight above 260 pounds (lbs)

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year.